Demonstrates cardiac safety of bimagrumab in older adults, suggesting its potential for muscle preservation during weight loss.
Six months of myostatin-activin pathway inhibition with bimagrumab had no effect on cardiac structure or function in healthy older adults compared to placebo. These results support consideration of bimagrumab as a skeletal muscle sparing intervention in adults undergoing weight loss with GLP-1 receptor agonists.
No takes yet. Share an insight, caveat, or question.
Rooks et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: